Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
140 participants
INTERVENTIONAL
2025-08-01
2028-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions of this project are:
1. Does RAS reduce severity of upper-limb bradykinesia (slow movements) and dyskinesia (repetitive and involuntary movements) after intervention, at 3-month follow-up and 6-month follow-up in SZ patients receiving second-generation antipsychotics? and
2. Does RAS reduce severity of upper-limb bradykinesia and dyskinesia after intervention, at 3-month follow-up and 6-month follow-up in SZ patients receiving first-generation antipsychotics?
Researchers will compare upper-limb movement training with the aid of RAS to upper-limb movement training without the aid of RAS to see if RAS works to improve upper-limb movements in SZ patients. Participants will:
1. Undergo an interview and movement tests and fill out questionnaires before and after the movement training program and at 3-month follow-up and 6-month follow-up; and
2. Receive movement training for 40 minutes per session for a total of 21 sessions.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Rhythmic Auditory Stimulation on Movements in Individuals at Risk for Psychotic Onset and Schizophrenia Patients
NCT04553835
Timing of Voluntary Movement in Patients With Schizophrenia
NCT00080548
Exploring the Effectiveness of Group Cognitive Stimulation Therapy in People With Schizophrenia.
NCT04916483
The Efficacy of Speech Competition Training on Auditory Hallucination in Schizophrenia
NCT05850923
The Effects of Simultaneous Training of Walking and Cognitive Tasks on Cognitive Functions of People With Schizophrenia
NCT04143308
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SZ patients receiving second-generation antipsychotics + RAS
SZ patients receiving second-generation antipsychotics: Provision of upper-limb movement training with the aid of RAS
RAS incorporated in upper-limb movement training
RAS will be metronome beat sound with different tempi and will be incorporated in upper-limb movement training, which will last for 40 minutes per session for a total of 21 sessions.
SZ patients receiving second-generation antipsychotics + no RAS
SZ patients receiving second-generation antipsychotics: Provision of upper-limb movement training without the aid of RAS
Upper-limb movement training
Upper-limb movement training will last for 40 minutes per session for a total of 21 sessions.
SZ patients receiving first-generation antipsychotics + RAS
SZ patients receiving first-generation antipsychotics: Provision of upper-limb movement training with the aid of RAS
RAS incorporated in upper-limb movement training
RAS will be metronome beat sound with different tempi and will be incorporated in upper-limb movement training, which will last for 40 minutes per session for a total of 21 sessions.
SZ patients receiving first-generation antipsychotics + no RAS
SZ patients receiving first-generation antipsychotics: Provision of upper-limb movement training without the aid of RAS
Upper-limb movement training
Upper-limb movement training will last for 40 minutes per session for a total of 21 sessions.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RAS incorporated in upper-limb movement training
RAS will be metronome beat sound with different tempi and will be incorporated in upper-limb movement training, which will last for 40 minutes per session for a total of 21 sessions.
Upper-limb movement training
Upper-limb movement training will last for 40 minutes per session for a total of 21 sessions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between 18 to 60 years old
* Keeping the same antipsychotics and the same dosage at least 4 weeks right before joining the study
* A Edinburgh Handedness Inventory score of \> 60
* A Montreal Cognitive Assessment score of ≥ 24
* Between 18 to 60 years old
* A Edinburgh Handedness Inventory score of \> 60
* A Montreal Cognitive Assessment score of ≥ 24
Exclusion Criteria
* Neurological diseases or medical conditions that affect upper-limb movements and hearing
* Other psychiatric diagnoses in addition to a diagnosis of schizophrenia or schizoaffective disorder
\[For healthy participants\]
* Substance abuse or drug abuse
* Neurological diseases or medical conditions that affect upper-limb movements and hearing
* Psychiatric diagnoses
* Taking psychotropic medications
* Presence of first-degree relatives or siblings with diagnoses of psychiatric diseases.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shu-Mei Wang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shu-Mei Wang
Dr.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Taipei University of Nursing and Health Sciences
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RAS in SZ
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.